Similar articles

• Minimizing cyclosporine concentration variability to optimize transplant outcome.

  Canafax DM. Canafax DM. Clin Transplant. 1995 Feb;9(1):1-13. Clin Transplant. 1995. PMID: 7742576 Review. No abstract available.
• [Cyclosporine].

  Schröder F, Herzig S. Schröder F, et al. Dtsch Med Wochenschr. 1998 Jan 30;123(5):121-2. doi: 10.1055/s-0029-1233213. Dtsch Med Wochenschr. 1998. PMID: 9487297 German. No abstract available.
• Comment: drug-herb interaction.

  Cheng TO. Cheng TO. Ann Pharmacother. 2001 Jan;35(1):124-5. doi: 10.1177/106002800103500101. Ann Pharmacother. 2001. PMID: 11197574 No abstract available.
• The interaction between clarithromycin and cyclosporine in kidney transplant recipients.

  Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y. Ferrari SL, et al. Transplantation. 1994 Sep 27;58(6):725-7. Transplantation. 1994. PMID: 7940695 No abstract available.
• Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.

  Strober S. Strober S. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.